Yao Zhengbin 4

What Happened
Yao Zhengbin, President, CEO and a director of ArriVent BioPharma, was granted a derivative award covering 550,000 shares on February 2, 2026. The grant is reported at $0.00 per share (a stock award/option-type grant), so there was no cash purchase or sale. The filing indicates this is an equity award rather than an open-market transaction.

Key Details

• Transaction date: 2026-02-02; Form 4 filed: 2026-02-04 (timely filing).
• Transaction type/code: A (award/grant of a derivative security); reported price: $0.00.
• Number of shares/units: 550,000 underlying shares granted.
• Vesting: 25% vests on Feb 2, 2027; the remainder vests in 36 equal monthly installments thereafter, subject to continued service (footnote F1).
• Shares owned after the transaction: not specified in the provided filing summary.
• No 10b5-1 plan, tax-withholding sale, or immediate sale reported.

Context
This is a compensation-related equity award, not a purchase or sale. The shares are subject to time-based vesting, so they are not immediately transferable or sold; their future receipt depends on continued service and vesting dates. Such grants are common for executives and reflect compensation arrangements rather than an immediate bullish or bearish trading signal.